Comparative effectiveness of two lipid emulsions in preventing retinopathy of prematurity in preterm infants requiring parenteral nutrition.

Autor:	Cabañas Poy MJ; Servicio de Farmacia, Hospital Universitari Vall d'Hebron, Barcelona, España. Electronic address: mjosep.cabanas@vallhebron.cat., Montoro Ronsano JB; Servicio de Farmacia, Hospital Universitari Vall d'Hebron, Barcelona, España., Castillo Salinas F; Servicio de Neonatología, Hospital Universitari Vall d'Hebron, Barcelona, España., Martín-Begué N; Unidad de Oftalmología Pediátrica, Hospital Universitari Vall d'Hebron, Barcelona, España., Clemente Bautista S; Servicio de Farmacia, Hospital Universitari Vall d'Hebron, Barcelona, España., Gorgas Torner MQ; Servicio de Farmacia, Hospital Universitari Vall d'Hebron, Barcelona, España.
Jazyk:	English; Spanish; Castilian
Zdroj:	Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria [Farm Hosp] 2024 Jul-Aug; Vol. 48 (4), pp. T159-T163. Date of Electronic Publication: 2024 May 20.
DOI:	10.1016/j.farma.2024.04.017
Abstrakt:	Objectives: The main aim was to compare the effects of two parenteral lipid emulsions on retinopathy of prematurity (ROP) incidence, severity, and need for treatment. Secondary aim was to compare the effect on weight gain in the first 6 weeks of life. Methods: Single-center, observational, retrospective study analyzing preterm infants with a gestational age < 31 weeks and a birth weight < 1,251 g, born between April 2015 and December 2018. The infants' medical records were reviewed to collect clinical data. Parenteral nutrition details were obtained from the hospital pharmacy database. Results: In total, 180 patients were included: 90 received ClinOleic® and 90 received SMOFlipid®. No significant differences were observed for the incidence of ROP (40% in ClinOleic® group and 41% in SMOFlipid® group, p=0.88) or ROP requiring treatment (4% and 10% respectively, p=0.152). Weekly weight gain was similar in the two groups. Conclusions: This study showed no difference between the two groups regarding ROP, ROP requiring treatment or weekly weight gain in the first 6 weeks of life. (Copyright © 2023 Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Publicado por Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu